Pub Date : 2025-01-01DOI: 10.1016/j.oraloncology.2024.107126
S. Hasan Pracha , Suvekshya Shrestha , Nathan Ryan , Puja Upadhaya , Felipe F. Lamenza , Sushmitha Jagadeesha , Pete Jordanides , Peyton Roth , Anna Springer , Steve Oghumu
Head and neck squamous cell carcinoma (HNSCC) is the 7th most common cancer globally with a 40–50 % survival rate. Although macrophage migration inhibitory factor (MIF) is overexpressed in most solid tumors and promotes tumor growth and invasion, the therapeutic potential of MIF inhibition in HNSCC is yet to be explored. In this study, we investigated the efficacy of CPSI-1306, a small-molecule MIF inhibitor, on HNSCC cell growth and cancer associated signaling pathways in vitro, as well as its impact on T cells in the HNSCC tumor microenvironment in vivo. CPSI-1306 did not reduce HNSCC cell proliferation in vitro, and mildly decreased VEGF and EGFR expression. However, CPSI-1306 significantly reduced tumor development in two orthotopic mouse oral cancer (MOC-2 and MOC-1) HNSCC models. Interestingly, CPSI-1306 treatment increased T cell infiltration to the tumor microenvironment and completely abrogated immunosuppressive checkpoint markers TIGIT, TIM3, and CTLA-4, but not PD-1 on tumor infiltrating CD8+ T cells. This was accompanied by increased CD8+ T cell expression of antitumoral cytokines IFN-γ and TNF-α in the draining lymph nodes and Granzyme B in the tumor microenvironment of CPSI-1306 treated tumor bearing mice. Our studies demonstrate that the small molecule MIF inhibitor CPSI-1306 potently inhibits T cell immunosuppression in the tumor microenvironment and reduces tumor growth in HNSCC. These studies open a novel therapeutic option for modulating anti-tumoral T cell immunity to improve HNSCC outcomes by targeting MIF.
{"title":"Targeting macrophage migration inhibitory factor to inhibit T cell immunosuppression in the tumor microenvironment and improve cancer outcomes in head and neck squamous cell carcinoma","authors":"S. Hasan Pracha , Suvekshya Shrestha , Nathan Ryan , Puja Upadhaya , Felipe F. Lamenza , Sushmitha Jagadeesha , Pete Jordanides , Peyton Roth , Anna Springer , Steve Oghumu","doi":"10.1016/j.oraloncology.2024.107126","DOIUrl":"10.1016/j.oraloncology.2024.107126","url":null,"abstract":"<div><div>Head and neck squamous cell carcinoma (HNSCC) is the 7th most common cancer globally with a 40–50 % survival rate. Although macrophage migration inhibitory factor (MIF) is overexpressed in most solid tumors and promotes tumor growth and invasion, the therapeutic potential of MIF inhibition in HNSCC is yet to be explored. In this study, we investigated the efficacy of CPSI-1306, a small-molecule MIF inhibitor, on HNSCC cell growth and cancer associated signaling pathways <em>in vitro</em>, as well as its impact on T cells in the HNSCC tumor microenvironment <em>in vivo</em>. CPSI-1306 did not reduce HNSCC cell proliferation <em>in vitro</em>, and mildly decreased VEGF and EGFR expression. However, CPSI-1306 significantly reduced tumor development in two orthotopic mouse oral cancer (MOC-2 and MOC-1) HNSCC models. Interestingly, CPSI-1306 treatment increased T cell infiltration to the tumor microenvironment and completely abrogated immunosuppressive checkpoint markers TIGIT, TIM3, and CTLA-4, but not PD-1 on tumor infiltrating CD8<sup>+</sup> T cells. This was accompanied by increased CD8<sup>+</sup> T cell expression of antitumoral cytokines IFN-γ and TNF-α in the draining lymph nodes and Granzyme B in the tumor microenvironment of CPSI-1306 treated tumor bearing mice. Our studies demonstrate that the small molecule MIF inhibitor CPSI-1306 potently inhibits T cell immunosuppression in the tumor microenvironment and reduces tumor growth in HNSCC. These studies open a novel therapeutic option for modulating anti-tumoral T cell immunity to improve HNSCC outcomes by targeting MIF.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"160 ","pages":"Article 107126"},"PeriodicalIF":4.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.oraloncology.2024.107136
Neil D. Almeida , Han Yu , Austin J. Iovoli , Mengyu Fang , Tyler V. Schrand , Abigail Pepin , Vishal Gupta , Kimberly E. Wooten , Michael R. Markiewicz , Ryan P. McSpadden , Wesley L. Hicks Jr , Mark K. Farrugia , Anurag K. Singh
Importance
The role of prophylactic percutaneous endoscopic gastrostomy (PEG) tube placement in head and neck cancer (HNC) patients treated with chemoradiation remains controversial and varies by center.
Objective
To evaluate the impact of prophylactic PEG tube placement in patients undergoing chemoradiation for HNC PEG tube use for more than 6 months and weight loss.
Design, Setting, and Participants
This single-institution retrospective study included 502 patients with head and neck cancer.
Exposures
Concurrent Chemoradiation (CCRT) and prophylactic PEG tube placement.
Main Outcomes and Measures
Univariate analyses were performed to determine risk factors for long term PEG tube and weight loss. Outcomes that were significantly associated with prophylactic PEG were selected for a multivariate analysis. The Kaplan-Meier method was used to estimate survival and the time to PEG removal, with comparisons between groups analyzed by log-rank tests. The global health status score from the EORTC QLQ30 was utilized to assess impact on quality of life.
Results
Significantly higher weight loss was seen with the following variables: 1) omitting prophylactic PEG tube (p < 0.00001), 2) younger age (p = 0.0032), and 3) adjuvant CCRT (p = 0.0005). There was significantly higher risk of feeding tube duration longer than 6 months in those who: received prophylactic PEG tube (p < 0.0001) and were older than the median age of 60.8 years (p = 0.0165) on multivariate analysis. Prophylactic PEG tube was not associated with improved global health status, overall survival, or progression-free survival on univariate analysis.
Conclusions and Relevance
Prophylactic feeding tubes significantly decreased weight loss during treatment. Prophylactic PEG tube and older than median age was significantly associated with higher risk of feeding tube duration longer than 6 months.
{"title":"Prophylactic gastrostomy tube during chemoradiation for head and neck cancer decreases weight loss but increases rate of tube use beyond six months","authors":"Neil D. Almeida , Han Yu , Austin J. Iovoli , Mengyu Fang , Tyler V. Schrand , Abigail Pepin , Vishal Gupta , Kimberly E. Wooten , Michael R. Markiewicz , Ryan P. McSpadden , Wesley L. Hicks Jr , Mark K. Farrugia , Anurag K. Singh","doi":"10.1016/j.oraloncology.2024.107136","DOIUrl":"10.1016/j.oraloncology.2024.107136","url":null,"abstract":"<div><h3>Importance</h3><div>The role of prophylactic percutaneous endoscopic gastrostomy (PEG) tube placement in head and neck cancer (HNC) patients treated with chemoradiation remains controversial and varies by center.</div></div><div><h3>Objective</h3><div>To evaluate the impact of prophylactic PEG tube placement in patients undergoing chemoradiation for HNC PEG tube use for more than 6 months and weight loss.</div></div><div><h3>Design, Setting, and Participants</h3><div>This single-institution retrospective study included 502 patients with head and neck cancer.</div></div><div><h3>Exposures</h3><div>Concurrent Chemoradiation (CCRT) and prophylactic PEG tube placement.</div></div><div><h3>Main Outcomes and Measures</h3><div>Univariate analyses were performed to determine risk factors for long term PEG tube and weight loss. Outcomes that were significantly associated with prophylactic PEG were selected for a multivariate analysis. The Kaplan-Meier method was used to estimate survival and the time to PEG removal, with comparisons between groups analyzed by log-rank tests. The global health status score from the EORTC QLQ30 was utilized to assess impact on quality of life.</div></div><div><h3>Results</h3><div>Significantly higher weight loss was seen with the following variables: 1) omitting prophylactic PEG tube (p < 0.00001), 2) younger age (p = 0.0032), and 3) adjuvant CCRT (p = 0.0005). There was significantly higher risk of feeding tube duration longer than 6 months in those who: received prophylactic PEG tube (p < 0.0001) and were older than the median age of 60.8 years (p = 0.0165) on multivariate analysis. Prophylactic PEG tube was not associated with improved global health status, overall survival, or progression-free survival on univariate analysis.</div></div><div><h3>Conclusions and Relevance</h3><div>Prophylactic feeding tubes significantly decreased weight loss during treatment. Prophylactic PEG tube and older than median age was significantly associated with higher risk of feeding tube duration longer than 6 months.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"160 ","pages":"Article 107136"},"PeriodicalIF":4.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.oraloncology.2024.107129
Hui Li , Liming Lou , Juan Du , Mei Li , Xianhui Wen , Yuan Zhang , Songran Liu , Zi-Qi Zheng , Xu Liu
Nasopharyngeal carcinoma (NPC), historically termed ‘lymphoepithelioma-like carcinoma’ due to its rich lymphocyte infiltration, benefit from PD-1 blockade treatment. However, a comprehensive understanding of its tumor microenvironment (TME) remains elusive, hindering the identification of effective biomarkers for immunotherapy. We leveraged multimodal profiling data, including gene expression, immunohistochemistry, and multiplex immunohistochemistry, from three independent cohorts of NPC patients with a total of 327 patients to dissect the TME in NPC. Unsupervised hierarchical clustering of TME cell populations in the discovery cohort revealed two novel subtypes with distinct prognosis: ‘Immune Inflamed’ and ‘Immune Deficient’. Intriguingly, the most significant differences between the two subtypes were the abundance of B cells and tertiary lymphoid structures (TLS), with a nearly two-fold increase in TLS presence in the Immune Inflamed subtype. The prognostic significance of TLS was confirmed in three independent NPC cohorts, surpassing the prognostic value of individual immune cell subsets. Mechanistically, TLS enhanced anti-tumor immunity by increasing T and B cell receptor repertoire diversity, promoting infiltration of plasma cells, macrophages, and natural killer cells, and consequently increasing antibody-dependent cell-mediated cytotoxicity and antibody-dependent phagocytosis. Finally, TLS status robustly predicted prognosis in a cohort of NPC patients treated with PD-1 blockade, and its prognostic value was consistent across a pan-cancer immunotherapy cohort of 10 tumors and 1158 patients, although with context-specific effects depending on cancer type and immunotherapy modality. In conclusion, this study provides compelling evidence that TLS is a robust indicator of overall immune response within TME and have great potential to guide individualized immunotherapy.
{"title":"Multimodal profiling uncovers tertiary lymphoid structures as a critical determinant of immunotherapy response and prognosis in nasopharyngeal carcinoma","authors":"Hui Li , Liming Lou , Juan Du , Mei Li , Xianhui Wen , Yuan Zhang , Songran Liu , Zi-Qi Zheng , Xu Liu","doi":"10.1016/j.oraloncology.2024.107129","DOIUrl":"10.1016/j.oraloncology.2024.107129","url":null,"abstract":"<div><div>Nasopharyngeal carcinoma (NPC), historically termed ‘lymphoepithelioma-like carcinoma’ due to its rich lymphocyte infiltration, benefit from PD-1 blockade treatment. However, a comprehensive understanding of its tumor microenvironment (TME) remains elusive, hindering the identification of effective biomarkers for immunotherapy. We leveraged multimodal profiling data, including gene expression, immunohistochemistry, and multiplex immunohistochemistry, from three independent cohorts of NPC patients with a total of 327 patients to dissect the TME in NPC. Unsupervised hierarchical clustering of TME cell populations in the discovery cohort revealed two novel subtypes with distinct prognosis: ‘Immune Inflamed’ and ‘Immune Deficient’. Intriguingly, the most significant differences between the two subtypes were the abundance of B cells and tertiary lymphoid structures (TLS), with a nearly two-fold increase in TLS presence in the Immune Inflamed subtype. The prognostic significance of TLS was confirmed in three independent NPC cohorts, surpassing the prognostic value of individual immune cell subsets. Mechanistically, TLS enhanced anti-tumor immunity by increasing T and B cell receptor repertoire diversity, promoting infiltration of plasma cells, macrophages, and natural killer cells, and consequently increasing antibody-dependent cell-mediated cytotoxicity and antibody-dependent phagocytosis. Finally, TLS status robustly predicted prognosis in a cohort of NPC patients treated with PD-1 blockade, and its prognostic value was consistent across a pan-cancer immunotherapy cohort of 10 tumors and 1158 patients, although with context-specific effects depending on cancer type and immunotherapy modality. In conclusion, this study provides compelling evidence that TLS is a robust indicator of overall immune response within TME and have great potential to guide individualized immunotherapy.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"160 ","pages":"Article 107129"},"PeriodicalIF":4.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-29DOI: 10.1016/j.oraloncology.2024.107111
Grégoire Marret , Constance Lamy , Sophie Vacher , Luc Cabel , Mathieu Séné , Ladidi Ahmanache , Laura Courtois , Zakhia El Beaino , Jerzy Klijanienko , Charlotte Martinat , Nicolas Servant , Choumouss Kamoun , Maral Halladjian , Thierry Bronzini , Cédric Balsat , Jean-François Laes , Aubray Prévot , Sébastien Sauvage , Maxime Lienard , Emmanuel Martin , Maud Kamal
Objectives
Head and neck squamous cell carcinoma (HNSCC) is characterized by significant genetic intra-tumor heterogeneity (ITH), which may hinder precision medicine strategies that depend on results from single tumor-biopsy specimens. Treatment response assessment relies on radiologic imaging, which cannot detect minimal residual disease (MRD). We assessed the relevance of circulating tumor DNA (ctDNA) as a biomarker for ITH and MRD in HNSCC.
Materials and methods
We recruited 41 non-metastatic resectable HNSCC patients treated with upfront curative-intent surgery in the prospective biobanking SCANDARE study (NCT03017573). Thirty-one patients (76 %) showed recurrent disease at a median follow-up of 41 months. Targeted next-generation sequencing was performed on resected tumor tissues, as well as on serial blood samples obtained at surgery, within 14 weeks after surgery, at six months and at recurrence.
Results
ctDNA was detected in 21/41 patients at surgery (sensitivity: 51 %; 95 % CI, 35–67 %) and 15/22 patients at recurrence (sensitivity: 68 %; 95 % confidence interval [CI], 45–86 %). Among patients with mutations identified in longitudinal plasma samples, additional mutations missed in tumor tissues were reported in 3/21 patients (14 %), while emerging mutations were reported in 9/21 patients (43 %). In the postoperative surveillance setting, ctDNA-based MRD detection anticipated clinical recurrence with a median lead-time of 9.9 months (interquartile range, 8.0–14.5 months) in 17/27 patients (63 %). When detected within 14 weeks after surgery, MRD correlated with disease recurrence after adjusting for classical prognostic variables (HR = 3.0; 95 % CI, 1.1–7.9; p = 0.03).
Conclusions
ctDNA detection is a useful biomarker for ITH and MRD in resectable HNSCC patients.
{"title":"Deciphering molecular relapse and intra-tumor heterogeneity in non-metastatic resectable head and neck squamous cell carcinoma using circulating tumor DNA","authors":"Grégoire Marret , Constance Lamy , Sophie Vacher , Luc Cabel , Mathieu Séné , Ladidi Ahmanache , Laura Courtois , Zakhia El Beaino , Jerzy Klijanienko , Charlotte Martinat , Nicolas Servant , Choumouss Kamoun , Maral Halladjian , Thierry Bronzini , Cédric Balsat , Jean-François Laes , Aubray Prévot , Sébastien Sauvage , Maxime Lienard , Emmanuel Martin , Maud Kamal","doi":"10.1016/j.oraloncology.2024.107111","DOIUrl":"10.1016/j.oraloncology.2024.107111","url":null,"abstract":"<div><h3>Objectives</h3><div>Head and neck squamous cell carcinoma (HNSCC) is characterized by significant genetic intra-tumor heterogeneity (ITH), which may hinder precision medicine strategies that depend on results from single tumor-biopsy specimens. Treatment response assessment relies on radiologic imaging, which cannot detect minimal residual disease (MRD). We assessed the relevance of circulating tumor DNA (ctDNA) as a biomarker for ITH and MRD in HNSCC.</div></div><div><h3>Materials and methods</h3><div>We recruited 41 non-metastatic resectable HNSCC patients treated with upfront curative-intent surgery in the prospective biobanking SCANDARE study (NCT03017573). Thirty-one patients (76 %) showed recurrent disease at a median follow-up of 41 months. Targeted next-generation sequencing was performed on resected tumor tissues, as well as on serial blood samples obtained at surgery, within 14 weeks after surgery, at six months and at recurrence.</div></div><div><h3>Results</h3><div>ctDNA was detected in 21/41 patients at surgery (sensitivity: 51 %; 95 % CI, 35–67 %) and 15/22 patients at recurrence (sensitivity: 68 %; 95 % confidence interval [CI], 45–86 %). Among patients with mutations identified in longitudinal plasma samples, additional mutations missed in tumor tissues were reported in 3/21 patients (14 %), while emerging mutations were reported in 9/21 patients (43 %). In the postoperative surveillance setting, ctDNA-based MRD detection anticipated clinical recurrence with a median lead-time of 9.9 months (interquartile range, 8.0–14.5 months) in 17/27 patients (63 %). When detected within 14 weeks after surgery, MRD correlated with disease recurrence after adjusting for classical prognostic variables (HR = 3.0; 95 % CI, 1.1–7.9; <em>p</em> = 0.03).</div></div><div><h3>Conclusions</h3><div>ctDNA detection is a useful biomarker for ITH and MRD in resectable HNSCC patients.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"160 ","pages":"Article 107111"},"PeriodicalIF":4.0,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-29DOI: 10.1016/j.oraloncology.2024.107128
Flávia Sirotheau Corrêa Pontes , Emilie Christina Teixeira de Barros , Thaís da Silva Fonseca , Igor Mesquita Lameira , Anderson Maurício Paiva e Costa , Douglas Fabrício da Silva Farias , Hélder Antônio Rebelo Pontes
{"title":"Synchronous adenoid cystic carcinoma in the submandibular gland and tongue: A rare case report","authors":"Flávia Sirotheau Corrêa Pontes , Emilie Christina Teixeira de Barros , Thaís da Silva Fonseca , Igor Mesquita Lameira , Anderson Maurício Paiva e Costa , Douglas Fabrício da Silva Farias , Hélder Antônio Rebelo Pontes","doi":"10.1016/j.oraloncology.2024.107128","DOIUrl":"10.1016/j.oraloncology.2024.107128","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"160 ","pages":"Article 107128"},"PeriodicalIF":4.0,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-29DOI: 10.1016/j.oraloncology.2024.107125
Tan Mai Nguyen , Pauline Quilhot , Isabelle Brochériou , Guillaume Rougier , Philippe Maingon , Chloé Bertolus , Jean-Philippe Foy
Oral squamous cell carcinoma (OSCC) is associated with an important mortality and morbidity related to surgery and radiotherapy. In particular, radiation-induced xerostomia has a major impact on patient’s quality of life. Although intensity-modulated radiation therapy allowed mean dose reduction to the spared submandibular gland (SMG) in patients with head and neck squamous cell carcinoma, xerostomia is still an important sequela for patients treated for an OSCC. SMG surgical transfer into anatomical subsite receiving very low radiation doses is a promising approach to prevent xerostomia. Based on a literature review and data from our institutional cohort, we analyzed the oncological safety of SMG preservation. Then, we discussed the feasibility and relevance of SMG transfer into the temporal fossa, in order to prevent radiation-induced xerostomia in patients with OSCC.
{"title":"Submandibular gland transfer into the temporal fossa in patients with oral squamous cell carcinoma: A viable option to prevent radiation-induced xerostomia","authors":"Tan Mai Nguyen , Pauline Quilhot , Isabelle Brochériou , Guillaume Rougier , Philippe Maingon , Chloé Bertolus , Jean-Philippe Foy","doi":"10.1016/j.oraloncology.2024.107125","DOIUrl":"10.1016/j.oraloncology.2024.107125","url":null,"abstract":"<div><div>Oral squamous cell carcinoma (OSCC) is associated with an important mortality and morbidity related to surgery and radiotherapy. In particular, radiation-induced xerostomia has a major impact on patient’s quality of life. Although intensity-modulated radiation therapy allowed mean dose reduction to the spared submandibular gland (SMG) in patients with head and neck squamous cell carcinoma, xerostomia is still an important sequela for patients treated for an OSCC. SMG surgical transfer into anatomical subsite receiving very low radiation doses is a promising approach to prevent xerostomia. Based on a literature review and data from our institutional cohort, we analyzed the oncological safety of SMG preservation. Then, we discussed the feasibility and relevance of SMG transfer into the temporal fossa, in order to prevent radiation-induced xerostomia in patients with OSCC.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"160 ","pages":"Article 107125"},"PeriodicalIF":4.0,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-26DOI: 10.1016/j.oraloncology.2024.107127
Eric L. Wu , Fendi Obuekwe , Joshua D. Smith , Mario G. Solari , Arturo A. Eguia , Tonge Enoh , Anthony Tang , Marci L. Nilsen , Jonas T. Johnson , Seungwon Kim , Kevin J. Contrera , Shaum S. Sridharan , Matthew E. Spector
{"title":"Towards improved speech and swallowing outcomes after hemiglossectomy reconstruction: Impact of neurotization and free flap choice","authors":"Eric L. Wu , Fendi Obuekwe , Joshua D. Smith , Mario G. Solari , Arturo A. Eguia , Tonge Enoh , Anthony Tang , Marci L. Nilsen , Jonas T. Johnson , Seungwon Kim , Kevin J. Contrera , Shaum S. Sridharan , Matthew E. Spector","doi":"10.1016/j.oraloncology.2024.107127","DOIUrl":"10.1016/j.oraloncology.2024.107127","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"160 ","pages":"Article 107127"},"PeriodicalIF":4.0,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142721995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-26DOI: 10.1016/j.oraloncology.2024.107092
Gnanaprakash Jeyaraj
{"title":"Letter to the editor, “Loss of MACROD2 drives radioresistance but not cisplatin resistance in HPV-positive head and neck cancer.”","authors":"Gnanaprakash Jeyaraj","doi":"10.1016/j.oraloncology.2024.107092","DOIUrl":"10.1016/j.oraloncology.2024.107092","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"160 ","pages":"Article 107092"},"PeriodicalIF":4.0,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142721996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-25DOI: 10.1016/j.oraloncology.2024.107120
Yanan Liu , Nantao Fu , Haitao Liu , Shanshan Su , Tingting Yang , Ping Long , Wei Zhong , Xiang Min
Objective
To analyze the clinicopathological features and predictors of lymph node metastasis (LNM) in the diffuse sclerosing variant of papillary thyroid carcinoma (DSV-PTC) and compare these findings with conventional papillary thyroid carcinoma (C-PTC) in pediatric populations.
Methods
Patients aged 18 years or younger who were preoperatively diagnosed with PTC and underwent thyroidectomy at the First Affiliated Hospitals of Nanchang University from January 2017 to May 2024 were included in this study. Demographic and clinicopathological characteristics were retrospectively analyzed. Univariate and multivariate analyses were performed to identify risk factors for lymph node metastasis. Clinical outcomes, including nerve injury, hypocalcemia, and recurrence, were also recorded and evaluated.
Results
A total of 119 children were enrolled in this study, with a median age of 15.6 years. Of these, 89 (74.8 %) were female, and 18 (15.1 %) were diagnosed with DSV-PTC. Central lymph node metastasis (CLNM) was observed in 94 (79 %) patients, while 60 (50.4 %) had lateral lymph node metastasis (LLNM). DSV-PTC was associated with a higher incidence of CLNM and LLNM compared to C-PTC (p = 0.039, p < 0.001). Multifocality and bilateral tumors were also more common in DSV-PTC (p < 0.001). Cox regression analysis identified tumor size as an independent predictive factor for CLNM in pediatric C-PTC patients. Tumor size, ETE and the presence of CLNM were independent predictive factors for LLNM. After a mean follow-up of 32.8 months, no patient died from the disease, but four C-PTC patients (4.0 %) developed local recurrences, which were managed surgically. Lung metastasis occurred in 2 (11.1 %)
DSV-PTC and 1(1.0 %)C-PTC patients, respectively. Permanent injuries included one case of unilateral recurrent laryngeal nerve(RLN) injury and two cases of bilateral RLN injury. Four patients (4.0 %) experienced temporary hypocalcemia, which resolved after 6 months of calcium therapy.
Conclusions
DSV-PTC presents unique characteristics of lymph node metastasis and may be more aggressive than conventional PTC in pediatric populations. The presence of CLNM, tumor size and ETE were identified as independent predictors of LLNM in pediatric patients with conventional PTC. Evaluating these prognostic factors may help in customizing individualized surgical approaches for children, thereby reducing unnecessary surgical complications.
{"title":"Risk factors of lymph node metastasis in the diffuse sclerosing variant of papillary thyroid carcinoma compared with conventional papillary thyroid carcinoma in pediatric populations","authors":"Yanan Liu , Nantao Fu , Haitao Liu , Shanshan Su , Tingting Yang , Ping Long , Wei Zhong , Xiang Min","doi":"10.1016/j.oraloncology.2024.107120","DOIUrl":"10.1016/j.oraloncology.2024.107120","url":null,"abstract":"<div><h3>Objective</h3><div>To analyze the clinicopathological features and predictors of lymph node metastasis (LNM) in the diffuse sclerosing variant of papillary thyroid carcinoma (DSV-PTC) and compare these findings with conventional papillary thyroid carcinoma (C-PTC) in pediatric populations.</div></div><div><h3>Methods</h3><div>Patients aged 18 years or younger who were preoperatively diagnosed with PTC and underwent thyroidectomy at the First Affiliated Hospitals of Nanchang University from January 2017 to May 2024 were included in this study. Demographic and clinicopathological characteristics were retrospectively analyzed. Univariate and multivariate analyses were performed to identify risk factors for lymph node metastasis. Clinical outcomes, including nerve injury, hypocalcemia, and recurrence, were also recorded and evaluated.</div></div><div><h3>Results</h3><div>A total of 119 children were enrolled in this study, with a median age of 15.6 years. Of these, 89 (74.8 %) were female, and 18 (15.1 %) were diagnosed with DSV-PTC. Central lymph node metastasis (CLNM) was observed in 94 (79 %) patients, while 60 (50.4 %) had lateral lymph node metastasis (LLNM). DSV-PTC was associated with a higher incidence of CLNM and LLNM compared to C-PTC (p = 0.039, p < 0.001). Multifocality and bilateral tumors were also more common in DSV-PTC (<em>p</em> < 0.001). Cox regression analysis identified tumor size as an independent predictive factor for CLNM in pediatric C-PTC patients. Tumor size, ETE and the presence of CLNM were independent predictive factors for LLNM. After a mean follow-up of 32.8 months, no patient died from the disease, but four C-PTC patients (4.0 %) developed local recurrences, which were managed surgically. Lung metastasis occurred in 2 (11.1 %)</div><div>DSV-PTC and 1(1.0 %)C-PTC patients, respectively. Permanent injuries included one case of unilateral recurrent laryngeal nerve(RLN) injury and two cases of bilateral RLN injury. Four patients (4.0 %) experienced temporary hypocalcemia, which resolved after 6 months of calcium therapy.</div></div><div><h3>Conclusions</h3><div>DSV-PTC presents unique characteristics of lymph node metastasis and may be more aggressive than conventional PTC in pediatric populations. The presence of CLNM, tumor size and ETE were identified as independent predictors of LLNM in pediatric patients with conventional PTC. Evaluating these prognostic factors may help in customizing individualized surgical approaches for children, thereby reducing unnecessary surgical complications.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"160 ","pages":"Article 107120"},"PeriodicalIF":4.0,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142704160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号